Liquid Biopsy: Personalized approaches for cancer
Liquid biopsy is transforming cancer diagnostics and treatment. This innovative method uses blood samples to analyze cell-free tumor-associated DNA (circulating tumor DNA, or ctDNA), circulating tumor cells (CTCs), and molecular biomarkers. It opens up a non-invasive and effective way to detect, monitor, and personalize cancer treatment. The specialized teams of experts across RGCC’s global laboratory network are at the forefront of cancer research, developing personalized supportive approaches for cancer patients. By leveraging cutting-edge technologies and advanced methodologies, RGCC is committed to continuously improving treatment outcomes and driving innovation in precision oncology.
RGCC: Innovation as a tradition
Founded by Dr. Ioannis Papasotiriou, RGCC International has been at the forefront of interdisciplinary cancer research and personalized oncology since 2004. Our expert teams have pursued a single mission for over 20 years: to deliver groundbreaking science which can lead to long-term remissions.
Our research focuses on each patient’s unique genetic profile and the specific biological characteristics of their tumor, enabling targeted, precision-driven treatment strategies designed to improve clinical outcomes.
Why RGCC tests rely on liquid biopsy
A brief explanation of biopsies
A biopsy is a medical procedure in which a tissue sample is taken directly from a tumor or suspicious area of the body for subsequent diagnostic evaluation. The collected tissue is examined under a microscope and analyzed at the protein and/or molecular level for cancer biomarkers to determine whether cancer is present and, if so, to identify its type and characteristics.
There are various types of tissue biopsies, including:
- Needle biopsy: A fine or core needle is used to take tissue samples from a tumor.
- Surgical biopsy: This involves taking a larger tissue sample or completely removing a tumor during a surgical procedure.
- Punch biopsy: In this procedure, a round tissue sample is taken using a special hollow needle. This method is used to check for certain types of cancer, including skin, vulvar, and cervical cancer.
- Endoscopic biopsy: This method is performed using a fiberoptic endoscope. Tissue samples are taken through a natural body orifice to internally obtain small amounts of tissue.
Limitations of conventional biopsies
Despite their importance in cancer diagnostics, conventional biopsies are associated with several limitations and risks. As invasive procedures, they are often painful and can cause complications such as bleeding, infection, or tissue damage.
Furthermore, they only provide information about the specific tissue sampled, even though tumors often consist of cells with diverse genetic characteristics. Due to the burden and potential risks, conventional biopsies are also unsuitable for routine monitoring of disease progression or for assessing treatment effectiveness. Liquid biopsy offers a more flexible and more comprehensive alternative, delivering meaningful results with a simple blood draw.
The future of oncology: Liquid biopsies as a tumor test
Unlike traditional biopsies, where tissue samples are taken directly from a tumor, liquid biopsies are based on a non-invasive blood test. Even the lowest number of individual tumor cells that enter the bloodstream can be detected and analyzed using modern methods. These circulating tumor cells provide valuable information about the immunophenotype and also the molecular characteristics of the cancer.
Precision oncology: Targeted diagnostics, individual treatments
While conventional treatments often follow standardized treatment protocols, precision oncology focuses on the unique genetic alterations of each tumor. Through comprehensive molecular analysis, precision oncology enables highly targeted, personalized cancer therapies that aim to improve effectiveness while reducing unnecessary toxicity.
Liquid biopsy plays a central role in advancing precision oncology. By examining circulating tumor cells (CTCs) in the blood, our tests deliver real-time insights into the molecular and protein characteristics of a tumor. This enables physicians to monitor treatment response closely and adjust therapies at an early stage when necessary.
In clinical practice, liquid biopsy supports the more efficient use of targeted therapies by enabling data-driven, patient-specific treatment decisions. At the same time, our technologies contribute to the development of innovative, tailored cancer drugs by helping researchers better identify and understand relevant molecular targets.
The combination of liquid biopsy and precision medicine holds significant potential: cancer therapies can become more effective, less invasive, and better aligned with each patient’s individual needs. Through these advancements, liquid biopsy is evolving into a cornerstone of personalized, predictive, and preventive oncology.
Applications of our liquid biopsy tests
Liquid biopsy plays a pivotal role in precision oncology by enabling minimally invasive, real-time insights into tumor biology. At RGCC International, we recognize the importance of a holistic, personalized treatment strategy supported by continuous medical monitoring.
Through advanced blood-based analyses, our liquid biopsy tests detect tumor-associated biomarkers and evaluate the potential effectiveness of cancer therapies and selected natural substances. This data-driven approach supports physicians in identifying and optimizing individualized treatment plans.
Liquid biopsy: Key Applications:
Early tumor detection
Even the smallest tumors can be detected early with our cancer blood tests, before they become detectable through imaging procedures or before symptoms appear.
Disease monitoring
Regular blood testing allows clinicians to assess how a tumor is responding to treatment and to identify early signs of progression.
Early detection of relapses (recurrences)
Liquid biopsy can detect relapses at a very early stage, often before they are clinically or radiologically detectable.
Personalized therapy
By analyzing tumor-associated genetic alterations, liquid biopsy enables targeted insights that support the selection of individualized treatment strategies tailored to the tumor’s specific molecular profile.
Therapy management
Because tumors may evolve genetically during treatment, ongoing liquid biopsy testing provides critical information to determine whether the therapy remains effective or requires adjustment.
Liquid biopsy: Which types of cancer can be analyzed?
We already use liquid biopsy to analyze a wide variety of cancers, such as breast, colon, GI, lung, melanoma, prostate, and sarcoma, among others. Analyses through liquid biopsy are particularly suitable for tumors that can be detected using CTCs in the blood. For tumors that do not shed CTCs, like those confined by the blood-brain barrier (brain tumors, glioblastomas), we analyze tissue samples taken directly from the affected area instead of blood samples.
Our Circulating Tumor Cells Analytical Method methods
Circulating tumor cells are shed from the primary tumor into the bloodstream. Their detection and characterization provide important information about tumor origin, disease stage, and metastatic risk.
Benefits for patients
Through liquid biopsy, we advance diagnostic and therapeutic strategies that support improved oncology care and patient outcomes. This minimally invasive approach offers several key advantages:
- Non-invasive: A simple blood draw is all that is needed. This makes liquid biopsy painless, safe, and complication-free.
- Repeatable: Since only a small amount of blood is needed, the examination can be repeated regularly to continuously monitor tumor development.
- Early detection of recurrence: Molecular changes can be identified before relapse becomes radiologically evident.
- Personalized therapy guidance: Detailed analysis of tumor DNA helps doctors develop tailored treatment strategies tailored to the tumor’s characteristics.
The future of cancer diagnostics: The role of liquid biopsy
Liquid biopsy is considered a cornerstone of precision oncology. Through the continuous refinement of our analytical technologies, we have developed a comprehensive portfolio of cancer blood tests. When combined with other diagnostic tools, such as imaging or genome sequencing, liquid biopsy can further enhance diagnostic accuracy and optimize treatments.
In clinical practice, we successfully use liquid biopsy to screen and monitor breast cancer, lung cancer, colon cancer, and many others. Our liquid biopsies support therapy management, early relapse detection, and the development of more personalized, less invasive treatment strategies.
RGCC International: Precise diagnostics with advanced technology
The RGCC International laboratory network offers a broad range of liquid biopsy tests specifically tailored to the needs of both patients and physicians. Our highly sensitive analytical methods deliver reliable results to support diagnostic evaluation, treatment planning, and ongoing disease monitoring.
Contact us to learn more about our liquid biopsy tests and their clinical applications. Together, we are working to shape the future of cancer diagnostics, advancing more precise and personalized cancer care.
